HRP20240564T1 - Novi farmaceutski sastav - Google Patents

Novi farmaceutski sastav Download PDF

Info

Publication number
HRP20240564T1
HRP20240564T1 HRP20240564TT HRP20240564T HRP20240564T1 HR P20240564 T1 HRP20240564 T1 HR P20240564T1 HR P20240564T T HRP20240564T T HR P20240564TT HR P20240564 T HRP20240564 T HR P20240564T HR P20240564 T1 HRP20240564 T1 HR P20240564T1
Authority
HR
Croatia
Prior art keywords
dosage form
oral administration
solid pharmaceutical
pharmaceutical dosage
administration according
Prior art date
Application number
HRP20240564TT
Other languages
English (en)
Croatian (hr)
Inventor
Douglas J. Demarini
Ngocdiep T. Le
Francisco HENRIQUEZ
Lihong Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20240564(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20240564T1 publication Critical patent/HRP20240564T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20240564TT 2010-12-20 2011-12-20 Novi farmaceutski sastav HRP20240564T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
EP22209107.6A EP4159205B1 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Publications (1)

Publication Number Publication Date
HRP20240564T1 true HRP20240564T1 (hr) 2024-09-27

Family

ID=46314827

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20240564TT HRP20240564T1 (hr) 2010-12-20 2011-12-20 Novi farmaceutski sastav
HRP20201409TT HRP20201409T1 (hr) 2010-12-20 2011-12-20 Novi farmaceutski pripravak
HRP20240563TT HRP20240563T1 (hr) 2010-12-20 2011-12-20 Novi farmaceutski sastav

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20201409TT HRP20201409T1 (hr) 2010-12-20 2011-12-20 Novi farmaceutski pripravak
HRP20240563TT HRP20240563T1 (hr) 2010-12-20 2011-12-20 Novi farmaceutski sastav

Country Status (38)

Country Link
US (5) US8580304B2 (enExample)
EP (4) EP4159204B1 (enExample)
JP (2) JP6126014B2 (enExample)
KR (1) KR101911109B1 (enExample)
CN (1) CN103998041B (enExample)
AR (2) AR084102A1 (enExample)
AU (1) AU2011349422B2 (enExample)
BR (1) BR112013015602B1 (enExample)
CA (1) CA2822701C (enExample)
CL (1) CL2013001779A1 (enExample)
CR (1) CR20130352A (enExample)
CY (1) CY1123376T1 (enExample)
DK (3) DK4159204T3 (enExample)
DO (1) DOP2013000138A (enExample)
EA (1) EA025198B1 (enExample)
ES (3) ES2820536T3 (enExample)
FI (2) FI4159204T3 (enExample)
HR (3) HRP20240564T1 (enExample)
HU (3) HUE066526T2 (enExample)
IL (1) IL226855A (enExample)
JO (1) JO3594B1 (enExample)
LT (3) LT4159204T (enExample)
MA (1) MA34883B1 (enExample)
MX (1) MX2013007073A (enExample)
MY (1) MY170501A (enExample)
NZ (1) NZ612157A (enExample)
PE (1) PE20140040A1 (enExample)
PH (1) PH12013501209A1 (enExample)
PL (3) PL4159204T3 (enExample)
PT (3) PT4159204T (enExample)
RS (2) RS65497B1 (enExample)
SG (1) SG191054A1 (enExample)
SI (3) SI2654736T1 (enExample)
TW (1) TWI505828B (enExample)
UA (1) UA113158C2 (enExample)
UY (1) UY33818A (enExample)
WO (1) WO2012088033A2 (enExample)
ZA (1) ZA201304189B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
PE20151024A1 (es) * 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
CN109789141B (zh) * 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
CA3041561A1 (en) * 2016-11-25 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (ko) 2008-07-08 2011-03-25 베타 파마, 인크. 염산 icotinib, 합성, 결정형, 약학적 조성물 및 이의 사용
BR112012006693A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
BR112012006485A2 (pt) 2009-09-23 2015-09-08 Glaxosmithkline Llc combinação
WO2011038380A2 (en) * 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
CN104382906A (zh) 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
JP5903433B2 (ja) * 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なvegfr阻害剤およびmek阻害剤の医薬的組み合わせ
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產(第二)有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
RS65497B1 (sr) 2024-06-28
EP4159204B1 (en) 2024-02-14
CN103998041B (zh) 2016-08-17
CA2822701C (en) 2018-10-23
US9399021B2 (en) 2016-07-26
PL2654736T3 (pl) 2020-12-14
US20120183613A1 (en) 2012-07-19
TW201249441A (en) 2012-12-16
EA201390913A1 (ru) 2014-04-30
US20140154316A1 (en) 2014-06-05
ES2985024T3 (es) 2024-11-04
CY1123376T1 (el) 2021-12-31
PL4159205T3 (pl) 2024-06-24
LT4159205T (lt) 2024-05-10
EP2654736A2 (en) 2013-10-30
SI2654736T1 (sl) 2020-10-30
EP4159204A1 (en) 2023-04-05
US9271941B2 (en) 2016-03-01
LT4159204T (lt) 2024-05-10
EP2654736A4 (en) 2015-04-22
HRP20240563T1 (hr) 2024-08-16
CL2013001779A1 (es) 2014-06-27
WO2012088033A3 (en) 2014-03-13
US20140099365A1 (en) 2014-04-10
PT4159204T (pt) 2024-05-07
DOP2013000138A (es) 2013-11-30
AR122185A2 (es) 2022-08-24
MA34883B1 (fr) 2014-02-01
RS65496B1 (sr) 2024-06-28
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
BR112013015602A2 (pt) 2017-02-21
CR20130352A (es) 2013-12-18
US9155706B2 (en) 2015-10-13
KR101911109B1 (ko) 2018-10-23
TWI505828B (zh) 2015-11-01
DK4159205T3 (da) 2024-05-13
PT4159205T (pt) 2024-05-08
AU2011349422B2 (en) 2015-12-10
PE20140040A1 (es) 2014-02-26
US20140037726A1 (en) 2014-02-06
PH12013501209A1 (en) 2013-07-29
CA2822701A1 (en) 2012-06-28
EP4159205A1 (en) 2023-04-05
HUE050788T2 (hu) 2021-01-28
ES2820536T3 (es) 2021-04-21
FI4159204T3 (fi) 2024-04-22
IL226855A (en) 2017-04-30
EA025198B1 (ru) 2016-11-30
MX2013007073A (es) 2013-09-26
UA113158C2 (xx) 2016-12-26
PT2654736T (pt) 2020-09-24
SI4159205T1 (sl) 2024-06-28
US8580304B2 (en) 2013-11-12
PL4159204T3 (pl) 2024-07-01
WO2012088033A2 (en) 2012-06-28
US20130266649A1 (en) 2013-10-10
AU2011349422A1 (en) 2013-05-02
KR20130130028A (ko) 2013-11-29
JO3594B1 (ar) 2020-07-05
HUE066526T2 (hu) 2024-08-28
SI4159204T1 (sl) 2024-06-28
FI4159205T3 (fi) 2024-04-23
ES2982775T3 (es) 2024-10-17
SG191054A1 (en) 2013-08-30
DK2654736T3 (da) 2020-09-14
JP2014510704A (ja) 2014-05-01
ZA201304189B (en) 2014-02-26
MY170501A (en) 2019-08-08
NZ612157A (en) 2015-05-29
JP2017137299A (ja) 2017-08-10
EP3808343A1 (en) 2021-04-21
AR084102A1 (es) 2013-04-24
LT2654736T (lt) 2020-09-25
EP4159205B1 (en) 2024-02-14
UY33818A (es) 2012-07-31
BR112013015602B1 (pt) 2022-03-03
JP6126014B2 (ja) 2017-05-10
CN103998041A (zh) 2014-08-20
HRP20201409T1 (hr) 2020-11-27
HUE066525T2 (hu) 2024-08-28

Similar Documents

Publication Publication Date Title
FI4159205T3 (fi) Uudenlainen farmaseuttinen koostumus
ES2248622T3 (es) Medicamento que contiene 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y que proporciona una liberacion retardada del principio activo.
RU2616516C2 (ru) Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
JP2009545560A5 (enExample)
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
HRP20211862T1 (hr) Pripravci za i postupci liječenja anemije
NO341027B1 (no) Tablett med høyt medikamentinnhold og fremgangsmåte for fremstilling derav
JP2016516698A5 (enExample)
MX337603B (es) Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
RU2008151950A (ru) Фармацевтическая лекарственная форма пролонгированного высвобождения, содержащая фенилэфрин
UA116334C2 (uk) Тверді форми дозування бендамустину
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
ES2435943T3 (es) Formulaciones de vildagliptina
HRP20161340T1 (hr) Formulacije darunavira
CA2858522A1 (en) Methods for treating cardiovascular disorder
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
JP2018527305A5 (enExample)
JP2019089796A5 (enExample)
JP2016530238A5 (enExample)
RU2014140177A (ru) Фармацевтические антиретровирусные композиции
WO2016062182A1 (zh) 一种普瑞巴林缓释制剂
EP3041511A2 (en) Compositions of eltrombopag
WO2012087255A2 (en) Pharmaceutical formulations
JP2019504024A5 (enExample)